Dihexa is a peptide that enhances the growth and development of neurons and synapses in the brain. Specifically, Dihexa has been shown to bind to and activate hepatocyte growth factor (HGF) receptors, which are found in high concentrations in the brain. Dihexa, also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amideor PNB-0408, is a relatively new drug for the treatment of Alzheimer’s disease (AD) and cognitive impairment. Unlike other drugs for AD, this potent nootropic does not only impede the progression of the disease but it actually repairs the damage in the synapse (junction) between neurons. Because of its regenerative properties, most medical professionals prescribe Dihexa for the treatment of a wide array of medical conditions that affect cognitive function.
Activation of HGF receptors by Dihexa has been shown to stimulate the growth and development of new neurons and synapses, which can lead to improvements in cognitive function, memory formation, and learning ability. Additionally, Dihexa has been shown to enhance the survival and function of existing neurons and synapses, which may help protect the brain from damage caused by conditions like Alzheimer’s disease and traumatic brain injury.
The therapeutic value of Dihexa, lies in its capacity to encourage the formation of new functional synaptic connections among existing neurons, encourage the replacement of damaged and lost neurons from available neural stem cell populations, and facilitate cerebral blood flow and neuroprotection. Such treatment outcomes would benefit patients afflicted with AD and possibly those suffering from other neurodegenerative diseases.
